Target intelligence / Profile preview

SPRY4 antisense RNA 1 (SPRY4-AS1)

Target: SPRY4-AS1
Molecular classification: Long noncoding RNA (lncRNA), Enhancer RNA (eRNA), Antisense RNA

Overview

SPRY4 antisense RNA 1 (SPRY4-AS1) is a long noncoding enhancer RNA located on chromosome 5, transcribed antisense to the SPRY4 gene. SPRY4-AS1 acts as a key regulator of gene expression, especially in cancer, where it modulates the expression of SPRY4 and other genes inside relevant oncogenic pathways. High SPRY4-AS1 expression is associated with tumor progression and poor prognosis in hepatocellular carcinoma and other malignancies. Its regulatory mechanisms involve interactions affecting cell cycle control, actin dynamics, and cell signaling cascades. SPRY4-AS1 is being evaluated as both a prognostic biomarker and a potential therapeutic target in oncology research.

Other names: THCAT68AC005592.2LINC01844

Mechanism of action

Gene expression modulation via enhancer activity, influencing tumor progression pathways like Hippo signaling and proteoglycan function in cancer. Positively regulates the SPRY4 gene, impacting cell signaling and survival.

Biological functions

Regulation of gene expression (especially SPRY4)Cell proliferationCell cycle regulationActin filament organizationIntracellular transportCellular protein localization

Disease associations

Cancer (most notably hepatocellular carcinoma, glioblastoma, adrenocortical carcinoma, lower grade glioma, mesothelioma)

Safety considerations

None directly discussed for SPRY4-AS1 targeting itselfGeneral concerns for RNA-targeting methods include off-target effectsDelivery challenges (inferred from antisense RNA therapeutic studies)

Biomarkers

SPRY4-AS1 expression levels (associated with poor prognosis in several cancers, especially hepatocellular carcinoma)

Beyond the preview

Go deeper on SPRY4 antisense RNA 1 (SPRY4-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPRY4 antisense RNA 1 (SPRY4-AS1).

Explore the full profile